[Duplex ultrasound measurement of blood flow in the superior mesenteric artery].
After a successful check of a duplex sonographic instrument in a water-bath, the following parameters were measured under standardised conditions in 30 fasting patients: blood flow rate in the mesenterica superior artery, maximal systolic, end-diastolic and average velocity as well as the vessel diameter. From these data the average blood flow rate was calculated. Maximal systolic velocity is on the average 134 +/- 22.8 cm/s, end diastolic 20.8 +/- 4.4 cm/s, average vascular diameter 7.6 +/- 0.7 mm, median blood flow 639 +/- 153 ml/min. Day-to-day variance is for the maximum systolic velocity at 11%, for end diastolic velocity at 9.7% and for the average vascular diameter at 2.2%. Postprandially the average flow velocity increases from 23.4 +/- 5.6 to 46 +/- 7.4 cm/s. The average vascular diameter increases from 7.6 +/- 0.7 to 8.0 +/- 0.8 mm. The median blood flow increases one hour after a non-standardised lunch by 126%. To show that Duplex sonography also covers pharmacodynamic blood flow changes, the maximum systolic, maximum diastolic and average velocity was measured before and 1 hour after ingestion of 20 mg nifedipine in 5 subjects. The measured parameters showed a significant increase.
Schäberle
W
W
Medizinische Klinik des Kreiskrankenhauses, Böblingen.
Seitz
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008638:Mesenteric Arteries / Q000000981:diagnostic imaging* / Q000187:drug effects; D008875:Middle Aged; D008955:Models, Cardiovascular; D009543:Nifedipine / Q000494:pharmacology; D012016:Reference Values; D014159:Transducers; D014463:Ultrasonography / Q000295:instrumentation*; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D009543:Nifedipine
Duplexsonographische Blutflussmessung in der Arteria mesenterica superior.